相关实验视频

Updated: Jul 23, 2025

Retroviral CRISPR/Cas9-Mediated Gene Targeting for the Study of Th17 Differentiation in Vitro

Retroviral CRISPR/Cas9-Mediated Gene Targeting for the Study of Th17 Differentiation in Vitro

Published on: November 15, 2024

在炎症和自身免疫性疾病中,用于Th17调节的RORγt小分子抑制剂

Jiuping Zeng^1,2, Mingxing Li^1,2,3, Qianyun Zhao^1,2

¹Laboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, Sichuan, 646000, China.

Journal of pharmaceutical analysis

|July 13, 2023

概括

视网相关孤儿受体γt (RORγt) 对于炎症性疾病至关重要. 针对RORγt的抑制剂在降低T辅助细胞17的发育和IL-17的产生方面表现出有希望的治疗效益.

科学领域:

免疫学免疫学免疫学
分子生物学分子生物学
药理学药理学是指药理学的学科.

背景情况:

视网相关孤儿受体γt (RORγt) 是一种依赖体的转录因子,对T辅助细胞17 (Th17) 的分化和17 (IL-17) 介素的表达至关重要.
在许多炎症和自身免疫性疾病的发病过程中,RORγt的作用至关重要,使其成为关键的治疗点.

研究的目的:

突出RORγt在Th17调节和相关的炎症/自身免疫性疾病中的作用.
总结RORγt抑制剂的最新进展,包括它们的开发,疗效和临床进展.

主要方法:

关于RORγt功能和抑制剂的文献综述.
对RORγt抗剂和逆激动剂的分析,这些抗剂准正或全结合部位.
检查小分子抑制剂,它们的优化,疗效,毒性,机制和临床试验数据.

主要成果:

已开发出RORγt抑制剂来调节Th17细胞发育和IL-17的产生.
几种小分子RORγt抑制剂已经进入临床评估阶段.
该审查详细介绍了抑制剂优化,疗效,毒性概况,作用机制和临床试验结果.

结论:

向RORγt为Th17介导的炎症和自身免疫性疾病提供了一个新的治疗策略.
目前正在进行的研究重点是优化RORγt抑制剂以提高有效性和安全性.
讨论当前的局限性旨在指导未来在这个治疗领域的研究和开发.

关键词:

自身免疫性疾病是一种自身免疫性疾病.炎症性疾病是一种炎症性疾病.罗尔特的时间.小分子抑制剂小分子抑制剂 T助手 17 帮助 17 帮助

更多相关视频

Author Spotlight: Achieving High-Purity In Vitro Differentiation of Th17 Cells Using Cytokine Concentration Modulation

Author Spotlight: Achieving High-Purity In Vitro Differentiation of Th17 Cells Using Cytokine Concentration Modulation

Published on: October 25, 2024

Isolation and Th17 Differentiation of Naïve CD4 T Lymphocytes

Isolation and Th17 Differentiation of Naïve CD4 T Lymphocytes

Published on: September 26, 2013

相关概念视频

T Cell Types and Functions

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...